GLP-1 FAQs

GLP-1 mimics a hormone called GLP-1 (glucagon-like peptide-1) that targets areas of the brain involved in regulating appetite and food intake. By slowing gastric emptying and increasing feelings of fullness, GLP-1 helps reduce caloric
intake, leading to weight loss.

For weight loss, GLP-1 is typically administered as a once-weekly subcutaneous injection. The dosage is gradually increased over a period of weeks to minimize side effects and help the body adjust to the medication.

GLP-1 for weight loss is generally prescribed for adults with a body mass index (BMI) of 30 or greater (obesity) or a BMI of 27 or greater (overweight) with at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol. It's important to undergo a thorough medical evaluation to determine eligibility and ensure the medication is safe based on individual health conditions.

Clinical trials have shown that patients taking GLP-1 for weight loss can achieve significant weight reduction. On average, patients may lose around 10-15% of their body weight over a period of 68 weeks. Individual results can vary based on adherence to the medication, diet, and exercise.

While GLP-1 has been shown to be effective and generally safe for weight loss, long-term data is still being collected. Potential risks may include pancreatitis, gallbladder disease, and an increased heart rate. Regular monitoring by a healthcare provider is essential to manage any potential risks and ensure the medication remains appropriate for the patient’s health needs.